Lapatinib
From Proteopedia
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1][2][3][4] | |||||
|---|---|---|---|---|---|
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | |||
| Tmax (hr) | 4 | 8 | |||
| Cmax (ng/ml) | 115 | 24.6 | |||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | |||
| Protein Binding (%) | 99 | 95 | |||
| T1/2 (hr) | 9.6 | 83 | |||
| AUC (ng/ml/hr) | 1429 | 1921 | |||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | |||
| Dosage (mg) | 100 | 50 | |||
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | |||
